Outcomes and Frequency of Salvage Cystectomy After Bladder-Sparing Therapy in MIBC

Overview

Bladder-sparing therapy (BST) with trimodal therapy (TMT) offers comparable oncologic outcomes to radical cystectomy (RC) in selected muscle-invasive bladder cancer (MIBC) patients. However, a notable proportion require salvage radical cystectomy (SV-RC) due to treatment failure or recurrence, with associated surgical challenges and potential complications.

Background

Muscle-invasive bladder cancer (MIBC) traditionally is treated with radical cystectomy (RC), but bladder-sparing therapy (BST) using maximal transurethral resection followed by radiochemotherapy (RCT) is increasingly supported as an alternative in well-selected patients. BST is preferred by many patients due to its minimally invasive nature and manageable toxicity. Despite this, some patients experience non-response or local recurrence necessitating salvage radical cystectomy (SV-RC), which can be complicated by irradiated tissue fragility and may impact quality of life differently than primary RC.

Data Highlights

A systematic review and meta-analysis included studies from 2000 to 2020 focusing on patients with ≥cT2N0/xM0 bladder cancer treated with BST including radiotherapy. The primary outcome was the pooled rate of SV-RC and associated surgical and oncologic outcomes. Secondary outcomes included variables linked to increased SV-RC likelihood. Data extraction and quality assessment were rigorously performed, with meta-analysis of proportions used to calculate pooled incidence rates and confidence intervals.

Key Findings

• BST with trimodal therapy (TMT) is supported by multiple guidelines as a curative alternative to primary RC in selected, compliant patients desiring bladder preservation.
• The pooled incidence rate of salvage radical cystectomy (SV-RC) following BST failure is significant but varies across studies.
• SV-RC is associated with increased surgical complexity and risk of perioperative complications due to irradiated tissue fragility.
• Early SV-RC (within 6 months of BST) is often performed for non-response or progressive disease, while later SV-RC addresses local recurrence.
• Patient selection criteria for BST (e.g., unifocal cT2 tumor, absence of carcinoma in situ or hydronephrosis) influence both BST success and outcomes after SV-RC.
• Quality of life after SV-RC may differ from primary RC, highlighting the importance of patient counseling and individualized treatment planning.

Clinical Implications

Clinicians should consider BST with TMT as a viable bladder-preserving option for well-selected MIBC patients, balancing the benefits of bladder retention against the risk of requiring SV-RC. Close monitoring is essential to identify treatment failure early and to optimize timing of SV-RC. Awareness of increased surgical risks after radiotherapy is critical for perioperative planning and patient counseling.

Conclusion

Bladder-sparing therapy offers comparable oncologic outcomes to radical cystectomy in selected MIBC patients but carries a risk of salvage cystectomy due to treatment failure. Understanding the frequency, timing, and outcomes of SV-RC is essential to optimize patient selection and management strategies.

References

1. Systematic Review and Meta-Analysis (2020) -- Outcomes and Frequency of Salvage Cystectomy Following Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer